相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment
Qi Chen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition
Mototsugu Kato et al.
HELICOBACTER (2019)
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
World trends for H-pylori eradication therapy and gastric cancer prevention strategy by H-pylori test-and-treat
Hidekazu Suzuki et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions
Alessia Savoldi et al.
GASTROENTEROLOGY (2018)
Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection
Wen Zhong Liu et al.
HELICOBACTER (2018)
Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study
Kanji Ohkuma et al.
JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION (2018)
Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication
Hiroki Tanabe et al.
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2018)
Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases
Xiaoxiao Yang et al.
DIGESTIVE DISEASES AND SCIENCES (2018)
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report
P. Malfertheiner et al.
GUT (2017)
Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis
James K. Y. Hooi et al.
GASTROENTEROLOGY (2017)
The Clinical Evidence Linking Helicobacter pylori to Gastric Cancer
Steven F. Moss
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2017)
Antibiotic resistance in Helicobacter pylori
Claudio Alba et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy
B. Moriyama et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection
William D. Chey et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations
Hirotoshi Echizen
CLINICAL PHARMACOKINETICS (2016)
Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)
Kazuyoshi Otake et al.
ADVANCES IN THERAPY (2016)
Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study
Yuuichi Sakurai et al.
ADVANCES IN THERAPY (2016)
Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
T. Kagami et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy
Sho Suzuki et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy
Kousaku Kawashima et al.
DIGESTIVE AND LIVER DISEASE (2016)
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
Kazunari Murakami et al.
GUT (2016)
Role of bismuth in improving Helicobacter pylori eradication with triple therapy
Maria Pina Dore et al.
GUT (2016)
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
Jyh-Ming Liou et al.
LANCET (2016)
Vonoprazan: First Global Approval
Karly P. Garnock-Jones
DRUGS (2015)
Current progress toward eradicating Helicobacter pylori in East Asian countries: Differences in the 2013 revised guidelines between China, Japan, and South Korea
Sun-Young Lee
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial
Peter Malfertheiner et al.
LANCET (2011)
Bismuth-Containing Quadruple Therapy as Second-Line Treatment for Helicobacter pylori Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate in Korea
Byoung Hwan Lee et al.
HELICOBACTER (2010)
Adverse events with bismuth salts for Helicobacter pylori eradication: Systematic review and meta-analysis
Alexander C. Ford et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Pharmacokinetics and bioequivalence of ranitidine and bismuth derived from two compound preparations
Quan Zhou et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication
J Spénard et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin
JF Westphal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Pharmacokinetic considerations in the eradication of Helicobacter pylori
U Klotz
CLINICAL PHARMACOKINETICS (2000)
分享论文
